Abstract OT1-04-01: Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy
Authors
Baird, RRamenatte, N
Watts, C
Jonson, A
Jones, L
Biggs, H
Harrison, E
Oberg, I
Bullen, G
Williams, M
Qian, W
Gilbert, F
Jodrell, D
Caldas, C
Karabatsou, K
Dunn, L
Jena, R
Whitfield, Gillian A
Chalmers, A
Jefferies, S
Price, S
Affiliation
Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire,Issue Date
2017-02-14
Metadata
Show full item recordCitation
Abstract OT1-04-01: Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy 2017, 77 (4 Supplement):OT1-04-01 Cancer ResearchJournal
Cancer ResearchDOI
10.1158/1538-7445.SABCS16-OT1-04-01Type
Meetings and ProceedingsLanguage
enISSN
0008-54721538-7445
ae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.SABCS16-OT1-04-01